Top Markets
#1 Black Phoenix Black Phoenix +350.87%
#2 Islamic Coin Islamic Coin +158.26%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.42%
#5 DOVU DOVU +18.91%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.19%
#7 Pons Pons +9.08%
#8 MarsCoin MarsCoin +8.69%
#9 stake.link stake.link +8.24%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +8.18%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Nanomix Corporation Nanomix Corporation

Nanomix Corporation

NNMX
Classificação em ações #41810
Boston Therapeutics, Inc. focuses on the discovery, production, and... Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
Preço da ação
$0.0002
Última sincronização: 2025-04-08
Valor de mercado
$9.80K
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Nanomix Corporation (NNMX)

Categoria

Healthcare
Histórico de dividendos de Nanomix Corporation (NNMX)
Nanomix Corporation (símbolo da ação: NNMX) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Nanomix Corporation (NNMX) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
173.00%
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
85.00%
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
178.00%
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
0.00%
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
0.00%
US